Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elesclomol - Synta Pharmaceuticals

Drug Profile

Elesclomol - Synta Pharmaceuticals

Alternative Names: Elesclomol sodium; STA-4783

Latest Information Update: 18 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Gynecologic Oncology Group; National Cancer Institute (USA); Synta Pharmaceuticals
  • Class Antineoplastics; Hydrazines; Ketones; Small molecules; Thiones
  • Mechanism of Action Apoptosis stimulants; Chelating agents; HSP70 heat shock protein stimulants; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Fallopian tube cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 15 Mar 2016 Synta Pharmaceuticals enter into an asset purchase agreement with a third party (Synta Pharmaceuticals, Form 10-K, March 2016)
  • 13 Aug 2015 Elesclomol is still in phase II trials for Ovarian cancer (Combination therapy, Second-line therapy or greater) in the USA
  • 09 Apr 2014 Discontinued - Phase-I for Prostate cancer (combination therapy, hormone refractory, late-stage disease, metastatic disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top